{"title":"A systematic review on cost-effectiveness of diagnostic methods and treatments for tuberculosis in India","authors":"Mohan Balakrishnan, Varadharajan R., Gajendran G.","doi":"10.1016/j.ijtb.2024.04.006","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Cost-effectiveness of a treatment is based on additional health benefits offered and for a test it is determined by fast and improved diagnosing capacity. Evidence on cost-effectiveness can help in identifying interventions that give optimal value for money and catalyse the effort of eliminating tuberculosis burden. Our objective is to evaluate and identify the cost-effectiveness of diagnostics and treatments for tuberculosis practiced in India from costing studies.</div></div><div><h3>Methods</h3><div>Electronic databases like PubMed, Web of Science, Scopus, ProQuest, Cochrane Library, and PlosOne are searched, from Jan 1995 to Jan 2023 based on the Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines. Quality of the selected studies is assessed using a consensus health economic criteria checklist.</div></div><div><h3>Results</h3><div><span>Among the twelve studies selected after quality assessment seven studies were on testing methods and five were on treatment interventions. The included, model-based studies used either state transition or decision tree model for cost analysis<span> primarily in a health system perspective. </span></span>Sputum smear microscopy test being dominated by other testing methods, strategies like public-private with right diagnostic method yields cost-effective results in tuberculosis healthcare.</div></div><div><h3>Conclusion</h3><div>Full economic evaluations on interventions for tuberculosis in India are scarce, particularly from patients’ perspective. The study provides holistic knowledge about the economic evaluations of tuberculosis tests and treatments, highlighting its applications and implemental complications for further development of improved strategies and economic evaluation.</div></div>","PeriodicalId":39346,"journal":{"name":"Indian Journal of Tuberculosis","volume":"72 ","pages":"Pages S28-S34"},"PeriodicalIF":0.0000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Tuberculosis","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0019570724000672","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
Cost-effectiveness of a treatment is based on additional health benefits offered and for a test it is determined by fast and improved diagnosing capacity. Evidence on cost-effectiveness can help in identifying interventions that give optimal value for money and catalyse the effort of eliminating tuberculosis burden. Our objective is to evaluate and identify the cost-effectiveness of diagnostics and treatments for tuberculosis practiced in India from costing studies.
Methods
Electronic databases like PubMed, Web of Science, Scopus, ProQuest, Cochrane Library, and PlosOne are searched, from Jan 1995 to Jan 2023 based on the Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines. Quality of the selected studies is assessed using a consensus health economic criteria checklist.
Results
Among the twelve studies selected after quality assessment seven studies were on testing methods and five were on treatment interventions. The included, model-based studies used either state transition or decision tree model for cost analysis primarily in a health system perspective. Sputum smear microscopy test being dominated by other testing methods, strategies like public-private with right diagnostic method yields cost-effective results in tuberculosis healthcare.
Conclusion
Full economic evaluations on interventions for tuberculosis in India are scarce, particularly from patients’ perspective. The study provides holistic knowledge about the economic evaluations of tuberculosis tests and treatments, highlighting its applications and implemental complications for further development of improved strategies and economic evaluation.
目的一种治疗的成本效益取决于所提供的额外健康效益,而一项检测的成本效益取决于快速和改进的诊断能力。有关成本效益的证据可以帮助确定具有最佳性价比的干预措施,并促进消除结核病负担的努力。我们的目标是通过成本研究来评估和确定印度结核病诊断和治疗的成本效益。方法检索1995年1月至2023年1月期间的PubMed、Web of Science、Scopus、ProQuest、Cochrane Library和PlosOne等电子数据库。所选研究的质量使用共识卫生经济标准清单进行评估。结果经质量评估后入选的12项研究中,7项研究涉及检测方法,5项研究涉及治疗干预措施。纳入的基于模型的研究主要从卫生系统的角度使用状态转换或决策树模型进行成本分析。痰涂片镜检在其他检测方法占主导地位的情况下,采用正确诊断方法的公私合作等策略在结核病医疗保健中产生了具有成本效益的结果。结论对印度结核病干预措施的全面经济评估很少,特别是从患者的角度。这项研究提供了关于结核病检测和治疗的经济评价的整体知识,强调了其应用和实施方面的复杂性,以便进一步制定改进的战略和经济评价。
期刊介绍:
Indian Journal of Tuberculosis (IJTB) is an international peer-reviewed journal devoted to the specialty of tuberculosis and lung diseases and is published quarterly. IJTB publishes research on clinical, epidemiological, public health and social aspects of tuberculosis. The journal accepts original research articles, viewpoints, review articles, success stories, interesting case series and case reports on patients suffering from pulmonary, extra-pulmonary tuberculosis as well as other respiratory diseases, Radiology Forum, Short Communications, Book Reviews, abstracts, letters to the editor, editorials on topics of current interest etc. The articles published in IJTB are a key source of information on research in tuberculosis. The journal is indexed in Medline